Stoke Therapeutics, Inc. (STOK) shareholders
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong Joint filing with RTW Investments, LP (9.90%) | 5,940,866 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (9.80%) | 5,600,920 | 9.80% | 13G (passive) amendment | Dec 31, 2025 |
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (9.99%) | 5,310,033 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| FMR LLC Joint filing with Abigail P. Johnson (7.50%) | 4,820,462 | 7.50% | 13G (passive) amendment | Sep 30, 2026 |
| Weston Nichols Joint filing with Lynx1 Capital Management LP (8.10%) | 4,763,673 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (6.70%), Redmile Biopharma Investments III, L.P. (5.60%) | 4,164,120 | 6.70% | 13G (passive) amendment | Mar 31, 2026 |
| Lynx1 Capital Management LP Joint filing with Weston Nichols (6.50%) | 4,038,404 | 6.50% | 13G (passive) amendment | Jun 30, 2026 |
| Skorpios Trust Joint filing with Montrago Trustees Ltd (7.20%), Blue Horizon Enterprise Ltd (5.40%) | 3,906,181 | 7.20% | 13D (active) amendment | Jun 4, 2025 |
| BlackRock, Inc. | 3,732,540 | 6.80% | 13G (passive) amendment | Sep 30, 2025 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (5.60%), Lampert Mark N (5.60%) and 1 more | 3,608,968 | 5.60% | 13G (passive) | Sep 23, 2026 |
| Morgan Stanley Joint filing with Morgan Stanley Capital Services LLC (5.40%) | 3,426,739 | 6.50% | 13G (passive) amendment | Dec 31, 2024 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (5.80%), Baker Bros. Advisors (GP) LLC (5.80%) and 1 more | 3,336,697 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (5.20%), Wellington Group Holdings LLP (5.20%) and 1 more | 3,095,700 | 5.20% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STOK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,877,357 | 9.11% | $192.31M | +491,643 | 0.00% |
| Rtw Investments, LP | 5,623,525 | 8.72% | $184.00M | – | 1.57% |
| FMR LLC | 5,313,100 | 8.23% | $173.84M | −70,566 | 0.01% |
| Lynx1 Capital Management LP | 4,038,404 | 6.26% | $132.14M | −725,269 | 15.27% |
| Redmile Group, LLC | 3,945,920 | 6.12% | $129.11M | −218,200 | 8.67% |
| Wellington Management Group Llp | 3,519,301 | 5.45% | $115.15M | +423,601 | 0.02% |
| Morgan Stanley | 3,452,795 | 5.35% | $112.98M | +29,515 | 0.01% |
| Baker Bros. Advisors LP | 3,336,697 | 5.17% | $109.18M | – | 0.55% |
| Toronto Dominion Bank | 3,173,258 | 4.92% | $103.83M | – | 0.12% |
| State Street Corp | 2,852,240 | 4.42% | $93.33M | +575,728 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,661,739 | 4.13% | $87.09M | +727,568 | 0.01% |
| Vanguard Capital Management LLC | 2,586,937 | 4.01% | $84.64M | +231,334 | 0.00% |
| Bvf Inc/Il | 2,547,557 | 3.95% | $83.36M | – | 2.13% |
| T. Rowe Price Investment Management, Inc. | 2,415,139 | 3.74% | $79.02M | +2,164,226 | 0.05% |
| Assenagon Asset Management S.A. | 2,256,776 | 3.50% | $73.84M | +1,349,761 | 0.05% |
| Siren, L.L.C. | 1,995,347 | 3.09% | $65.29M | – | 1.32% |
| Deerfield Management Company, L.P. (Series C) | 1,823,500 | 2.83% | $59.66M | – | 0.62% |
| Jupiter Topco LLC | 1,814,408 | 2.81% | $59.36M | New | 0.02% |
| Geode Capital Management, LLC | 1,524,309 | 2.36% | $49.88M | +202,049 | 0.00% |
| Dimensional Fund Advisors LP | 1,013,911 | 1.57% | $33.17M | +23,975 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 198 | 77M | 100.0% | 31 / 77 | 57 / 28 | 11M | 4M |
| Q1 2026 | 198 | 71M | 100.0% | 44 / 80 | 52 / 27 | 12M | 5M |
| Q4 2025 | 183 | 67M | 100.0% | 46 / 54 | 58 / 13 | 8M | 7M |
| Q3 2025 | 151 | 68M | 100.0% | 38 / 47 | 41 / 20 | 8M | 6M |
| Q2 2025 | 133 | 66M | 100.0% | 23 / 51 | 33 / 16 | 9M | 7M |
| Q1 2025 | 126 | 63M | 98.2% | 24 / 44 | 31 / 27 | 8M | 3M |
| Q4 2024 | 130 | 58M | 90.3% | 29 / 39 | 42 / 16 | 9M | 9M |
| Q3 2024 | 118 | 59M | 90.8% | 24 / 38 | 36 / 20 | 10M | 9M |
| Q2 2024 | 115 | 63M | 97.0% | 34 / 48 | 22 / 22 | 15M | 15M |
| Q1 2024 | 103 | 63M | 96.9% | 32 / 36 | 26 / 9 | 16M | 2M |
| Q4 2023 | 81 | 49M | 75.4% | 7 / 28 | 30 / 21 | 8M | 3M |
| Q3 2023 | 96 | 44M | 68.1% | 17 / 26 | 36 / 20 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
232 funds held STOK in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of STOK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2,260,550 | 3.50% | $65.24M | 0.17% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,884,647 | 2.92% | $61.67M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,573,585 | 2.44% | $51.49M | 0.48% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,413,700 | 2.19% | $46.26M | 0.06% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,293,694 | 2.00% | $39.99M | 0.76% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 729,201 | 1.13% | $23.86M | 0.16% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 643,537 | 1.00% | $21.06M | 0.02% | Jun 30, 2026 |
| Select Health Care Portfolio | 628,000 | 0.97% | $19.41M | 0.34% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 602,340 | 0.93% | $17.38M | 0.05% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 520,825 | 0.81% | $15.03M | 0.17% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 508,416 | 0.79% | $16.64M | 0.11% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 495,887 | 0.77% | $16.23M | 0.17% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 473,152 | 0.73% | $14.63M | 0.25% | May 29, 2026 |
| Fidelity Stock Selector Small Cap Fund | 435,300 | 0.67% | $12.56M | 0.17% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 418,934 | 0.65% | $13.71M | 0.11% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ian F. Smith | Chief Executive Officer, Director | – | – | Feb 19, 2026 |
| Barry Ticho | CHIEF MEDICAL OFFICER | 11,864 | 0.02% | Nov 4, 2026 |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | 20,598 | 0.03% | Oct 2, 2026 |
| Thomas McCauley | Chief Scientific Officer | – | – | Jul 17, 2026 |
| Jason Hoitt | Chief Patient Officer | 10,276 | 0.02% | Mar 19, 2026 |
| Thomas Leggett | Chief Financial Officer | 10,381 | 0.02% | Mar 19, 2026 |
| Alexander Cumbo | Director | – | – | Sep 25, 2026 |
| Edward M. Kaye MD | Director | 125,194 | 0.19% | Aug 18, 2026 |
| Seth Loring Harrison | Director | 17,161,713 | 26.60% | Jul 17, 2026 |
| Arthur Tzianabos | Director | 35,694 | 0.06% | Jun 5, 2026 |
| Julie Smith | Director | 0 | – | Jun 5, 2026 |
| Jennifer Burstein | Director | 0 | – | Jun 5, 2026 |
| Adrian R. Krainer | Director | 283,302 | 0.44% | Jun 5, 2026 |
| Arthur A. Levin | Director | 22,216 | 0.03% | Jun 5, 2026 |
| Clare Kahn | Director | – | – | Apr 7, 2026 |
| Garry E. Menzel | Director | 0 | – | Jun 4, 2025 |
| Trustees Ltd Montrago | 10% owner | 14,443,681 | 22.38% | Jun 6, 2025 |
| Horizon Enterprise Ltd Blue | 10% owner | 6,906,181 | 10.70% | Jun 6, 2025 |
| International Ltd Ezbon | 10% owner | – | – | Jun 6, 2025 |
| Trust Skorpios | 10% owner | 3,906,181 | 6.05% | Jun 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Barry Ticho CHIEF MEDICAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −200 | $26.99 | $5.40K | 11,864 |
| Barry Ticho CHIEF MEDICAL OFFICER | Nov 2, 2026 | Sale(10b5-1 plan) | −6,995 | $26.38 | $184.51K | 12,064 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Oct 2, 2026 | Sale(10b5-1 plan) | −627 | $26.33 | $16.51K | 20,598 |
| Barry Ticho CHIEF MEDICAL OFFICER | Oct 1, 2026 | Sale(10b5-1 plan) | −1,051 | $26.16 | $27.49K | 19,059 |
| Barry Ticho CHIEF MEDICAL OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −3,945 | $30.51 | $120.36K | 21,710 |
| Barry Ticho CHIEF MEDICAL OFFICER | Sep 1, 2026 | Sale(10b5-1 plan) | −1,600 | $31.06 | $49.70K | 20,110 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Aug 18, 2026 | Sale | −2,716 | $32.01 | $86.94K | 21,370 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Aug 18, 2026 | Sale | −145 | $32.47 | $4.71K | 21,225 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 18, 2026 | Sale | −4,525 | $32.01 | $144.85K | 25,897 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 18, 2026 | Sale | −242 | $32.47 | $7.86K | 25,655 |
| Edward M. Kaye MD Director | Aug 18, 2026 | Sale | −11,930 | $32.01 | $381.88K | 125,194 |
| Edward M. Kaye MD Director | Aug 18, 2026 | Sale | −637 | $32.47 | $20.68K | 124,557 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Aug 14, 2026 | Option exercise | +6,000 | – | – | 24,086 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 14, 2026 | Option exercise | +10,000 | – | – | 30,422 |
| Edward M. Kaye MD Director | Aug 14, 2026 | Option exercise | +26,250 | – | – | 137,124 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −1,269 | $29.45 | $37.37K | 20,422 |
| Barry Ticho CHIEF MEDICAL OFFICER | Aug 3, 2026 | Sale(10b5-1 plan) | −5,907 | $28.95 | $171.01K | 21,691 |
| Barry Ticho CHIEF MEDICAL OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −6,728 | $32.62 | $219.47K | 28,098 |
| Barry Ticho CHIEF MEDICAL OFFICER | Jul 1, 2026 | Sale(10b5-1 plan) | −500 | $33.27 | $16.64K | 27,598 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Jun 16, 2026 | Sale(10b5-1 plan) | −1,457 | $29.95 | $43.64K | 18,086 |
| Barry Ticho CHIEF MEDICAL OFFICER | Jun 1, 2026 | Sale(10b5-1 plan) | −1,795 | $30.58 | $54.89K | 34,826 |
| Barry Ticho CHIEF MEDICAL OFFICER | May 1, 2026 | Sale(10b5-1 plan) | −2,243 | $32.79 | $73.55K | 36,621 |
| Barry Ticho CHIEF MEDICAL OFFICER | Apr 1, 2026 | Sale(10b5-1 plan) | −1,838 | $32.66 | $60.03K | 38,864 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 20, 2026 | Sale(10b5-1 plan) | −601 | $34.41 | $20.68K | 19,543 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 20, 2026 | Sale(10b5-1 plan) | −8,692 | $33.64 | $292.40K | 20,144 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 19, 2026 | Option exercise | +1,365 | $2.19 | $2.99K | 42,163 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 19, 2026 | Sale(10b5-1 plan) | −1,461 | $29.99 | $43.82K | 40,702 |
| Thomas Leggett Chief Financial Officer | Mar 18, 2026 | Sale | −2,173 | $31.28 | $67.97K | 10,381 |
| Thomas Leggett Chief Financial Officer | Mar 18, 2026 | Sale | −172 | $31.79 | $5.47K | 10,209 |
| Thomas Leggett Chief Financial Officer | Mar 18, 2026 | Sale | −37 | $32.85 | $1.22K | 10,172 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 18, 2026 | Sale | −334 | $31.79 | $10.62K | 28,908 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 18, 2026 | Sale | −72 | $32.85 | $2.37K | 28,836 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 18, 2026 | Sale | −4,222 | $31.28 | $132.06K | 29,242 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 18, 2026 | Sale(10b5-1 plan) | −483 | $31.79 | $15.35K | 40,901 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 18, 2026 | Sale(10b5-1 plan) | −103 | $32.85 | $3.38K | 40,798 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 18, 2026 | Sale(10b5-1 plan) | −6,100 | $31.28 | $190.81K | 41,384 |
| Jason Hoitt Chief Patient Officer | Mar 18, 2026 | Sale | −30 | $32.85 | $986 | 10,276 |
| Jason Hoitt Chief Patient Officer | Mar 18, 2026 | Sale | −1,762 | $31.28 | $55.12K | 10,445 |
| Jason Hoitt Chief Patient Officer | Mar 18, 2026 | Sale | −139 | $31.79 | $4.42K | 10,306 |
| Thomas Leggett Chief Financial Officer | Mar 17, 2026 | Sale | −1,274 | $32.74 | $41.71K | 13,476 |
| Thomas Leggett Chief Financial Officer | Mar 17, 2026 | Sale | −922 | $33.38 | $30.78K | 12,554 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 17, 2026 | Sale | −1,791 | $33.38 | $59.78K | 33,464 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 17, 2026 | Sale | −2,476 | $32.74 | $81.06K | 35,255 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale(10b5-1 plan) | −2,587 | $33.38 | $86.35K | 47,484 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale(10b5-1 plan) | −3,577 | $32.74 | $117.11K | 50,071 |
| Jason Hoitt Chief Patient Officer | Mar 17, 2026 | Sale | −1,033 | $32.74 | $33.82K | 12,955 |
| Jason Hoitt Chief Patient Officer | Mar 17, 2026 | Sale | −748 | $33.38 | $24.97K | 12,207 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 15, 2026 | Option exercise | +7,475 | – | – | 19,731 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 15, 2026 | Option exercise | +12,000 | – | – | 37,731 |
| Jonathan Allan GENERAL COUNSEL & CORP SEC | Mar 15, 2026 | Option exercise | +6,000 | – | – | 25,731 |
| Edward M. Kaye MD Director | Mar 15, 2026 | Option exercise | +26,250 | – | – | 110,874 |
| Edward M. Kaye MD Director | Mar 15, 2026 | Option exercise | +35,500 | – | – | 84,624 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +10,000 | – | – | 42,898 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +13,100 | – | – | 32,898 |
| Barry Ticho CHIEF MEDICAL OFFICER | Mar 15, 2026 | Option exercise | +10,750 | – | – | 53,648 |
| Thomas Leggett Chief Financial Officer | Mar 15, 2026 | Option exercise | +14,750 | – | – | 14,750 |
| Jason Hoitt Chief Patient Officer | Mar 15, 2026 | Option exercise | +10,000 | – | – | 13,988 |
| Arthur A. Levin Director | Mar 13, 2026 | Sale(10b5-1 plan) | −605 | $36.80 | $22.26K | 4,237 |
| Adrian R. Krainer Director | Mar 10, 2026 | Sale(10b5-1 plan) | −33,243 | $39.74 | $1.32M | 283,302 |
| Arthur Tzianabos Interim Executive Chair, Director | Mar 10, 2026 | Option exercise | +3,955 | $8.33 | $32.95K | 35,694 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Stoke Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,076 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Edward M. Kaye MD Former Affiliate | Oct 21, 2026 | 1,496,042 | $38.42M | Oct 21, 2026 | Exercise of Options Under a Registered Plan |
| Jonathan Allan Officer | Oct 2, 2026 | 627 | $16.31K | Oct 2, 2026 | Restricted Stock Units |
| Baruch Ticho Officer | Aug 3, 2026 | 20,967 | $605.11K | Aug 3, 2026 | Restricted Stock Units |
| Baruch S. Ticho Officer | Jul 1, 2026 | 7,228 | $236.50K | Jul 1, 2026 | Restricted Stock Units |
| Jonathan Allan Officer | Jun 16, 2026 | 1,457 | $43.71K | Jun 16, 2026 | Restricted Stock Units |
| Baruch S. Ticho Officer | May 1, 2026 | 4,038 | $132.12K | May 1, 2026 | Restricted Stock Units |
| Baruch S. Ticho Officer | Apr 1, 2026 | 1,838 | $59.85K | Apr 1, 2026 | Restricted Stock Units |
| Jonathan Allan Officer | Mar 20, 2026 | 9,293 | $308.43K | Mar 20, 2026 | Restricted Stock Units |
| Baruch S. Ticho Officer | Mar 19, 2026 | 1,461 | $45.32K | Mar 19, 2026 | Exercise of Stock Options |
| Arthur A. Levin Director | Mar 13, 2026 | 605 | $22.07K | Mar 13, 2026 | Restricted Stock Units |
| Arthur Tzianabos Director | Mar 10, 2026 | 90,508 | $3.47M | Mar 10, 2026 | Exercise of Stock Options |
| Adrian R. Krainer Director | Mar 2, 2026 | 40,472 | $1.47M | Mar 2, 2026 | Founders Shares |
| Edward M. Kaye MD Director | Dec 8, 2025 | 13,430 | $414.58K | Dec 8, 2025 | Performance Stock Units |
| Jonathan Allan Officer | Dec 8, 2025 | 3,978 | $122.80K | Dec 8, 2025 | Performance Stock Units |
| Jonathan Allan Officer | Dec 5, 2025 | 7,781 | $241.60K | Dec 5, 2025 | Restricted Stock Units |
See a number that looks wrong?